Provided by Tiger Fintech (Singapore) Pte. Ltd.

Edgewise Therapeutics, Inc.

16.68
+0.28001.71%
Post-market: 16.750.0700+0.42%17:17 EDT
Volume:1.09M
Turnover:18.21M
Market Cap:1.75B
PE:-11.52
High:16.89
Open:16.39
Low:16.17
Close:16.40
Loading ...

Edgewise Therapeutics Inc - Sevasemten Was Well-Tolerated and No New Safety Concerns Were Observed

THOMSON REUTERS
·
16 Dec 2024

Edgewise Therapeutics Inc - Trial Met Primary Endpoint of Change in CK Levels

THOMSON REUTERS
·
16 Dec 2024

Edgewise Therapeutics Announces Positive Topline Results From the Canyon Phase 2 Trial of Sevasemten in Individuals With Becker Muscular Dystrophy (Becker)

THOMSON REUTERS
·
16 Dec 2024

Edgewise Therapeutics Clarifies FDA Warning Unrelated to Clinical Trials, Data

MT Newswires Live
·
06 Dec 2024

Edgewise weakness on FDA warning letter ‘unwarranted,’ says RBC Capital

TIPRANKS
·
06 Dec 2024

BRIEF-Edgewise Provides Statement Regarding Company’S Relationship With Dr. Han Phan

Reuters
·
06 Dec 2024

Edgewise Therapeutics Shares Down 2.7% in Volume Spike

THOMSON REUTERS
·
06 Dec 2024

Edgewise says FDA warning letter unrelated to any Edgewise clinical trial, data

TIPRANKS
·
06 Dec 2024

Edgewise Provides Statement Regarding Company’s Relationship With DR. Han Phan at Rare Disease Research

THOMSON REUTERS
·
06 Dec 2024

Edgewise Therapeutics: Warning Letter by FDA to DR. Han Phan Is Unrelated to Any Edgewise Clinical Trial or Data

THOMSON REUTERS
·
06 Dec 2024

Edgewise Therapeutics- Believes Data Related to Co's Clinical Trials at Phan's Site Are Acquired & Stored in Accordance With FDA Requirements

THOMSON REUTERS
·
06 Dec 2024

Edgewise should be bought on weakness as ARCH not likely FDA focus, says Truist

TIPRANKS
·
06 Dec 2024

Edgewise falls after FDA posts Warning Letter to trial investigator

TIPRANKS
·
06 Dec 2024

Edgewise Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
28 Nov 2024

Edgewise Therapeutics price target raised to $50 from $33 at Truist

TIPRANKS
·
27 Nov 2024

Truist Raises Price Target on Edgewise Therapeutics to $50 From $33, Keeps Buy Rating

MT Newswires Live
·
27 Nov 2024

Truist Financial Sticks to Their Buy Rating for Edgewise Therapeutics (EWTX)

TIPRANKS
·
27 Nov 2024

Edgewise Therapeutics Inc : Truist Securities Raises Target Price to $50 From $33

THOMSON REUTERS
·
27 Nov 2024

Edgewise Therapeutics Inc : Truist Securities Raises Target Price to $50 From $33

THOMSON REUTERS
·
27 Nov 2024

JPMorgan updates its U.S. Analyst Focus List – Adds TPR, ALRM, REG

seekingalpha
·
26 Nov 2024